Liver-infiltrating CD8+ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma

Liver International

Volumn 36, Issue 3, 2016, Pages 434-444

  Ramzan, Muhammad ^a,b   Sturm, Nathalie ^a,b,c   Decaens, Thomas ^a,b,c   Bioulac Sage, Paulette ^d   Bancel, Brigitte ^e,f,g   Merle, Philippe ^e,f,g   Tran Van Nhieu, Jeanne ^h   Slama, Rémy ^a,b   Letoublon, Christian ^a,b,c   Zarski, Jean Pierre ^a,b,c   Jouvin Marche, Evelyne ^a,b   Marche, Patrice N ^a,b,c   Leroy, Vincent ^a,b,c  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

Hepatitis C Virus; Hepatocellular carcinoma; Liver infiltrating lymphocytes; Natural Killer cell

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CD8ALPHA ANTIGEN; CD8BETA ANTIGEN; CELL MARKER; GAMMA INTERFERON; INTERLEUKIN 6; PERFORIN; RANTES; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR GAMMA DELTA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; AUTACOID; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; COHORT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; AGED; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COMPLICATION; FRANCE; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; VIROLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FRANCE; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MICROENVIRONMENT;

EID: 84958910885     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12927     Document Type: Article

References (45)

1. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
2. EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
3. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
4. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-50.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
6. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002; 16: 217-26, 229; discussion 230-212.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
8. Laghi L, Bianchi P, Miranda E, et al. CD3 + cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10: 877-84.
9. Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology (Baltimore, MD) 1998; 27: 407-14.
10. Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52: 370-9.
11. Fu J, Zhang Z, Zhou L, et al. Impairment of CD4 + cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology (Baltimore, MD) 2013; 58: 139-49.
12. Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating FOXP3 + regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008; 34: 173-9.
13. Zhou J, Ding T, Pan W, et al. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125: 1640-8.
14. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-39.
15. Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5.
16. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25: 2586-93.
17. Cariani E, Pilli M, Zerbini A, et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS ONE 2012; 7: e32493.
18. Huang Y, Wang FM, Wang T, et al. Tumor-infiltrating FoxP3 + Tregs and CD8 + T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 2012; 86: 329-37.
19. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83.
20. Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61: 427-38.
21. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-12e1502.
22. Chen KJ, Zhou L, Xie HY, et al. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Med Oncol 2012; 29: 1817-26.
23. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
24. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
25. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71: 5670-7.
26. Gao Q, Zhou J, Wang XY, et al. Infiltrating memory/senescent T cell ratio predicts extrahepatic metastasis of hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 455-66.
27. Cai XY, Wang JX, Yi Y, et al. Low counts of gammadelta T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev 2014; 15: 775-80.
28. Sturm N, Thelu MA, Camous X, et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010; 53: 25-35.
29. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104: 595-603.
30. Unitt E, Rushbrook SM, Marshall A, et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology (Baltimore, MD) 2005; 41: 722-30.
31. Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110-5.
32. Roberts SJ, Ng BY, Filler RB, et al. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci USA 2007; 104: 6770-5.
33. Wang J, Zhao W, Cheng L, et al. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. J Immunol 2010; 185: 7654-62.
34. Regimbeau JM, Abdalla EK, Vauthey JN, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004; 85: 36-41.
35. Duncan AW, Dorrell C, Grompe M. Stem cells and liver regeneration. Gastroenterology 2009; 137: 466-81.
36. Leroy V, Vigan I, Mosnier JF, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology (Baltimore, MD) 2003; 38: 829-41.
37. Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-43.
38. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80: 1197-213.
39. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
40. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31: 787-98.
41. Meier UC, Owen RE, Taylor E, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005; 79: 12365-74.
42. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009; 51: 458-67.
43. Guo CL, Yang HC, Yang XH, et al. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev 2012; 13: 5909-13.
44. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002; 29: 5-11.
45. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25 + T cells. Immunology 2002; 107: 5-9.